top of page
Incubate Coalition
Jan 17
Incubate Responds to Next 15 Drugs Selected for Medicare Price Controls
WASHINGTON (January 17) -- Today, the Centers for Medicare & Medicaid Services announced the second round of Medicare Part D drugs...
Incubate Coalition
Jan 12
Incubate Survey Finds That Drug Price Controls Create Headwinds for Life Sciences Startups
WASHINGTON ( January 13 ) -- Today, Incubate Policy Lab released insights from a survey of life sciences venture capital investors about...
Incubate Coalition
Sep 20, 2024
Looking back and looking ahead: A momentous (and misguided) time for drug pricing policy
August was a momentous month for the life sciences ecosystem, and September looks to be just as significant. In this blog post, we want...
Incubate Coalition
Aug 15, 2024
Incubate responds to Maximum Fair Prices for first 10 drugs selected for Medicare price controls
WASHINGTON (August 15) -- Today, the Biden administration announced Maximum Fair Prices (MFPs) for the first 10 drugs selected for...
Incubate Coalition
Jun 12, 2024
Incubate Launches Life Science Investment Tracker to Analyze Impact of the Inflation Reduction Act
WASHINGTON (June 13) -- Today, Incubate launched the Life Science Investment Tracker, a database monitoring changes in investment,...
Incubate Coalition
Feb 7, 2024
Incubate Submits Letter On HELP Committee Hearing
Incubate is an international coalition of life science venture capitalists committed to educating policymakers on the role of venture...
Incubate Coalition
Feb 1, 2024
Life Sciences Investors Applaud Bipartisan Bill To Eliminate Small-Molecule Penalty
This bipartisan legislation would eliminate the small-molecule penalty by aligning the price-setting timeline for small and large...
Incubate Coalition
Dec 7, 2023
Life Sciences Investors React To Biden Administration’s March-In Decision
After a nine-month review, the Biden administration has reached the unprecedented and misguided conclusion that the 1980 Bayh-Dole Act...
Incubate Coalition
Nov 20, 2023
What Is Up For Biopharmaceutical Policy In 2024?
Incubate and DLA Piper invite you to join us on the morning of Sunday, January 7th, as part of JPM Week 2024. Attendees will gain an...
Incubate Coalition
Oct 11, 2023
Mary R. Grealy On The Small Molecule Penalty, U.S. Dominance In Life Sciences, And More
Incubate Executive Director John Stanford sat down this week with Mary R. Grealy, CEO of the Healthcare Leadership Council, to discuss...
Incubate Coalition
Sep 25, 2023
Incubate Releases Statement On Fitch Ratings’ Analysis Of Medicare Drug Price Negotiations
Fitch Ratings recently released an analysis showing that Medicare's drug price negotiation program is expected to deter investments into...
Incubate Coalition
Aug 28, 2023
Life Sciences Investors React To First 10 Drugs Selected For Government Price Controls
Executive Director John Stanford issued a statement in response. WASHINGTON, D.C. (August 29,2023) — Today, the Centers for Medicare &...
Incubate Coalition
Jul 9, 2023
Incubate Submits Comment In Response To Draft Legislation To Reauthorize PAHPA
Incubate recently submitted comment in response to the Senate HELP Committee’s draft legislation to reauthorize the Pandemic and...
Incubate Coalition
May 21, 2023
Massachusetts Biotech Community Calls On Congress To Fix The Small Molecule Penalty
Given the tremendous focus of MA-based companies and investors, we had an opportunity to pen some thoughts which are shared in the...
Incubate Coalition
Apr 16, 2023
Incubate Submits Comment To CMS Regarding Its Draft Guidance For The Medicare Drug Price Negotiation Program
Incubate submitted our feedback to the Centers for Medicare & Medicaid Services regarding its draft guidance for the Medicare Drug Price...
bottom of page